Vesigenurtucel-L

Drug Profile

Vesigenurtucel-L

Alternative Names: HS-410; UM-UC-3-gp96-Ig-HLA-A1; vesigenurtacel-L

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Heat Biologics
  • Class Adjuvants; Cancer vaccines; Cell therapies; Heat shock proteins; Tumour cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer

Most Recent Events

  • 21 Mar 2017 Vesigenurtucel-L is still in phase II trials for Bladder cancer (Adjuvant therapy, Combination therapy) and Bladder cancer (Monotherapy) in USA (Intradermal)
  • 17 Feb 2017 Interim efficacy data from a phase II trial in Bladder cancer released by Heat Biologics
  • 11 Oct 2016 Heat Biologics and Adaptive Biotechnologies collaborate for immune response assay for vesigenurtucel-L
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top